🔎 Trials Near Me

Home › Schizophrenia › Washington

Schizophrenia clinical trials in Washington

8 studies for Schizophrenia are looking for participants at sites in Washington.

Cities in Washington

Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

  • Neurocrine Clinical Site, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07227818

NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

  • Neurocrine Clinical Site, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07114874

Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  • Northwest Clinical Research Center, Bellevue
  • Core Clinical Research, Everett
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 25, 2026 · NCT06229210

A Study of Brenipatide in Adult Participants With Schizophrenia

  • Northwest Clinical Research Center, Bellevue
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Sep 22, 2026 · NCT07410507

A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

  • Local Institution - 0155, Everett
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 22, 2026 · NCT07424404

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder

  • Alkermes Investigator Site, Everett
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Aug 14, 2026 · NCT05303064

Randomized Withdrawal Study in Patients With Schizophrenia

  • Vanda Investigational Site, Bellevue
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jan 12, 2026 · NCT06961968

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

  • Vanda Investigational Site, Everett
RecruitingPhase 4
Ages 12 to 17 · All sexes · Updated Mar 4, 2025 · NCT05648591

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.